(Q39901709)

15 September 2017

title

Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation (English)

1 reference

15 September 2017

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Frank Stämmler

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

D Weber

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

P J Oefner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

K Dettmer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

J Koestler

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

A Gessner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

M Weber

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

J Hahn

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

D Wolff

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

W Herr

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

E Holler

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

21 March 2016

1 reference

Bone Marrow Transplantation

15 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1087-1092

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26999466%20AND%20SRC:MED&resulttype=core&format=json

The microbiome revolution

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Rifaximin pharmacology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Variations in 1 alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 serum levels during allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

An open-label evaluation of rifaximin in the treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders--A Focus on the Modulation of Host Tissue Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Pregnane X receptor as a target for treatment of inflammatory bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2016.66

Rifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activation

21 January 2018

1 reference

12 December 2020

Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final result

1 reference

12 December 2020

Graft-versus-host disease

1 reference

12 December 2020

Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora

1 reference

12 December 2020